文献速递白血病

Uproleselan联合化疗治疗复发或难治性急性髓系白血病的1/2期研究

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
PubMed 文献 · Blood · 2022-01-01

该1/2期研究评估了E-选择素拮抗剂uproleselan联合MEC方案治疗复发/难治性AML的安全性及抗白血病活性,确定推荐2期剂量为10 mg/kg每日两次。在该剂量下,复发/难治患者完全缓解/完全缓解伴计数不完全恢复率为41%,中位总生存期8.8个月;初诊老年患者联合7+3方案CR/CRi率为72%,中位OS 12.6个月,且口腔黏膜炎发生率低。

要点

  • Uproleselan联合MEC在复发/难治AML中耐受良好,推荐2期剂量为10 mg/kg每日两次。
  • 推荐2期剂量下复发/难治AML的CR/CRi率为41%,中位OS为8.8个月。
  • 初诊老年AML联合7+3方案CR/CRi率达72%,中位OS 12.6个月,黏膜炎发生率低。

核心结论

  • Uproleselan联合化疗耐受良好,缓解率高、诱导死亡率低、黏膜炎发生率低,支持开展3期随机确证研究。

研究设计与样本

  • 1/2期研究,评估uproleselan(5-20 mg/kg)联合MEC方案治疗复发/难治AML。
  • 前19例患者未观察到剂量限制性毒性,推荐2期剂量为10 mg/kg每日两次。
  • 额外47例复发/难治AML患者接受推荐2期剂量联合MEC治疗。
  • 另25例年龄≥60岁初诊患者接受推荐2期剂量联合阿糖胞苷和伊达比星(7+3)治疗。

主要发现

  • 推荐2期剂量下复发/难治AML的CR/CRi率为41%(CR 35%),中位OS为8.8个月。
  • 初诊老年患者CR/CRi率为72%(CR 52%),中位OS为12.6个月。
  • 加用uproleselan与低口腔黏膜炎发生率相关。
  • 复发AML患者白血病原始细胞E-选择素配体表达高于原发难治AML。
  • 复发/难治队列中E-选择素表达>10%与更高缓解率和改善生存相关。

关键数值与推荐

  • 推荐2期剂量为10 mg/kg每日两次。
  • 复发/难治AML:CR/CRi率41%(CR 35%),中位OS 8.8个月。
  • 初诊老年AML:CR/CRi率72%(CR 52%),中位OS 12.6个月。
  • E-选择素表达>10%与更高缓解率和改善生存相关。

临床怎么用

  • Uproleselan联合化疗可作为复发/难治及初诊老年AML的潜在治疗选择,需3期随机研究确认。
  • E-选择素表达>10%可能有助于筛选获益人群。

局限性

  • 为1/2期研究,样本量有限,结论需3期随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A phase 1/2 study evaluated the safety, tolerability, and antileukemic activity of uproleselan (5-20 mg/kg) with MEC (mitoxantrone, etoposide, and cytarabine) among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Among the first 19 patients, no dose-limiting toxicities were observed. The recommended phase 2 dose (RP2D) was 10 mg/kg twice daily. An additional 47 patients with R/R AML were treated with uproleselan at the RP2D plus MEC. At the RP2D, the remission rate (complete response [CR]/CR with incomplete count recovery [CRi]) was 41% (CR, 35%), and the median overall survival (OS) was 8.8 months. In a separate cohort, 25 newly diagnosed patients age ≥60 years received uproleselan at the RP2D plus cytarabine and idarubicin (7 + 3). In these frontline patients, the CR/CRi rate was 72% (CR, 52%), and the median OS was 12.6 months. The addition of uproleselan was associated with low rates of oral mucositis. E-selectin ligand expression on leukemic blasts was higher in patients with relapsed vs primary refractory AML and in newly diagnosed older patients with high-risk cytogenetics and secondary AML. In the R/R cohort, E-selectin expression >10% was associated with a higher response rate and improved survival. The addition of uproleselan to chemotherapy was well tolerated, with high remission rates, low induction mortality, and low rates of mucositis, providing a strong rationale for phase 3 randomized confirmatory studies. This trial was registered at www.clinicaltrials.gov as #NCT02306291.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. DeAngelo DJ, Jonas BA, Liesveld JL, et al. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022. PMID: 34543383. doi:10.1182/blood.2021010721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。